ManagedCareHemo.com Presents: Collaborating to Improve Care for Hemophilia: Managed Care Strategies for the Evolving Treatment Paradigm
Jointly provided by
Postgraduate Institute for Medicine    National Hemophilia Foundation   
This activity is supported by independent educational grants from Novo Nordisk and uniQure biopharma B.V.

Live Virtual Symposium Date
DayTimeRegister
Friday, April 16, 2021 9:00am-10:30am ET Click here to register

Prior to this virtual symposium, please review the primer to see the latest in hemophilia treatment.
Start now at: ManagedCareHemo.com/ClinicalPrimer
LEARN ABOUT
  • Recently approved and emerging hemophilia treatment options
  • Hemophilia-related complications associated with inhibitor development
  • Processes to improve communication and collaboration with hemophilia treatment centers (HTCs)
EXPERT FACULTY PRESENTERS
James T. Kenney, RPh, MBA
Founder and President
JT Kenney, LLC
Vanita K. Pindolia, PharmD, BCPS
Vice President, Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System/Health Alliance Plan of Michigan
Mark T. Reding, MD
Associate Professor of Medicine
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
TARGET AUDIENCE

The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, members of the AMCP, and other managed health care professionals attending the AMCP 2021 Managed Care and Specialty Pharmacy Annual Meeting.

PROGRAM OVERVIEW

The management of hemophilia is complex; however, appropriate management is vital to minimizing and/or preventing complications that contribute to worse health outcomes and higher health care resource utilization. Education is needed to operationalize and implement well-coordinated patient management, the most cost-effective ways of using available treatments, and the importance of collaboration among all stakeholders, which includes leveraging the success of the comprehensive care model utilized by hemophilia treatment centers (HTCs).

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Describe recent insights into the safety, efficacy, and unique attributes of recently approved and emerging hemophilia treatment options.
  • Assess the integration of the evolving treatment paradigm within the current hemophilia treatment algorithm.
  • Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences.
  • Apply processes for managed care and specialty pharmacy professionals to improve communication and collaboration with HTCs.
AGENDA
5 Minutes Opening Comments/Overview
James T. Kenney, RPh, MBA

30 Minutes Clinical Update on the Evolving Hemophilia Treatment Paradigm
Mark T. Reding, MD

20 Minutes Treatment Algorithm Integration of Novel Therapies in a Cost-Conscious Environment
Vanita K. Pindolia, PharmD, BCPS

20 Minutes Applying Processes to Enhance Hemophilia Patient Outcomes
James T. Kenney, RPh, MBA

15 Minutes Audience Question and Answer Session
Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
ACCREDITATION INFORMATION
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the National Hemophilia Foundation and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-21-2143-L01-P
Type of Activity: Knowledge

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.